Zimmer Biomet (NYSE:ZBH) Shares Cross Below 50-Day Moving Average – Time to Sell?

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $94.86 and traded as low as $94.38. Zimmer Biomet shares last traded at $94.54, with a volume of 3,605,958 shares.

Analysts Set New Price Targets

ZBH has been the subject of several research analyst reports. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Royal Bank Of Canada increased their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday. Seven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $104.47.

Zimmer Biomet Price Performance

The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The company has a market cap of $18.03 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 2.34 and a beta of 0.49. The company has a fifty day simple moving average of $94.86 and a two-hundred day simple moving average of $91.70.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s payout ratio is presently 23.36%.

Insider Activity

In other news, insider Chad F. Phipps sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This trade represents a 4.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at $922,000. Hsbc Holdings PLC purchased a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $35,417,000. Legal & General Group Plc acquired a new position in shares of Zimmer Biomet during the second quarter worth $126,167,000. Rakuten Investment Management Inc. purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $2,945,000. Finally, Nykredit A S acquired a new stake in Zimmer Biomet during the 2nd quarter valued at approximately $3,419,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.